

DAFTAR PUSTAKA

1. Organization WH. *Global tuberculosis report 2016*. 2016.
2. Infodatin. Pusat Data dan Informasi Kementerian Kesehatan RI. Jakarta: Kementerian Kesehatan RI, 2018 ISSN 2442-7659.
3. Permenkes No. 67 Tahun 2017 Tentang: Penanggulangan Tuberkulosis, Departemen Kesehatan Republik Indonesia, (2017).
4. Wijayanti Y. Faktor Risiko Yang Berhubungan Dengan Kejadian Multi-Drug Resistant Tuberculosis (TB MDR) di RSUP dr. Sardjito Yogyakarta: Universitas Gadjah Mada; 2017.
5. Organization WH. *Global tuberculosis report 2015*: World Health Organization; 2015.
6. Organization WH. *Global tuberculosis report 2018*. 2018.
7. Indonesia PMKR. Pedoman Manajemen Terpadu Pengendalian Tuberkulosis Resistan Obat. Jakarta: PerMenKes RI. 2013;13.
8. Indonesia KKR. Pedoman nasional pengendalian tuberkulosis. Direktorat Jendral Pengendalian Penyakit Dan Penyehatan Lingkungan, Jakarta, Indonesia, ISBN. 2014:978-9.
9. Andriyanti AS. Faktor Risiko Kejadian Tuberkulosis Resisten Obat Ganda (TB ROG). Abstrak. 2014.
10. Sarpal S, Goel N, Kumar D, Janmeja A. *Reasons for interruption of anti-tubercular treatment among the retreatment patients in category II of RNTCP in Chandigarh, north India*. The Indian journal of tuberculosis. 2014;61(2):121-8.
11. ade Bagiada I, Primasari NLP. Faktor-faktor yang mempengaruhi tingkat ketidakpatuhan penderita tuberkulosis dalam berobat di Poliklinik DOTS RSUP Sanglah Denpasar. 2010.
12. Chan-Yeung M, Noertjojo K, Leung C, Chan S, Tam C. *Prevalence and predictors of default from tuberculosis treatment in Hong Kong*. 2003.
13. Reichman LB, Hershfield ES. *Tuberculosis: a comprehensive international approach*: CRC Press; 2000.
14. Ruru Y, Matasik M, Oktavian A, Senyorita R, Mirino Y, Tarigan LH, et al. *Factors associated with non-adherence during tuberculosis treatment among patients treated with DOTS strategy in Jayapura, Papua Province, Indonesia*. *Global health action*. 2018;11(1):1510592.
15. Farmani PI, Wirawan DN, Sawitri AAS, Putra IAE. *Predictors of treatment interruption among tuberculosis patients in public health centres in Bali, Indonesia*. *Public Health and Preventive Medicine Archive*.5(2):165-73.
16. Noerfitri. Analisis Survival Pengaruh Rujuk Balik dan Tipe Pasien terhadap Kejadian Loss To Follow Up pada Pasien Multi-Drug Resistant Tuberculosis di Indonesia tahun 2014-2015: Universitas Indonesia; 2018.
17. Masini EO, Mansour O, Speer CE, Addona V, Hanson CL, Sitienei JK, et al. *Using survival analysis to identify risk factors for treatment interruption among new and retreatment tuberculosis patients in Kenya*. *PloS one*. 2016;11(10):e0164172.

18. Lalor MK, Greig J, Allamuratova S, Althomsons S, Tigay Z, Khaemraev A, et al. *Risk factors associated with default from multi-and extensively drug-resistant tuberculosis treatment, Uzbekistan: a retrospective cohort analysis*. PloS one. 2013;8(11):e78364.
19. Habteyes Hailu T, Azar T, Davoud Shojaeizadeh GG. *Tuberculosis treatment non-adherence and lost to follow up among TB patients with or without HIV in developing countries: a systematic review*. Iranian journal of public health. 2015;44(1):1.
20. Vasudevan K, Jayakumar N, Gnanasekaran D. *Smear conversion, treatment outcomes and the time of default in registered tuberculosis patients on RNTCP DOTS in Puducherry, Southern India*. Journal of clinical and diagnostic research: JCDR. 2014;8(10):JC05.
21. Alobu I, Oshi SN, Oshi DC, Ukwaja KN. *Risk factors of treatment default and death among tuberculosis patients in a resource-limited setting*. Asian Pacific journal of tropical medicine. 2014;7(12):977-84.
22. Andersen R. Andersen and Newman *Framework of Health Services Utilization*. Journal of Health and Social Behavior. 1995;36:1-10.
23. Naing NN, D'Este C, Isa AR, Salleh R, Bakar N, Mahmud MR. *Factors contributing to poor compliance with anti-TB treatment among tuberculosis patients*. Southeast Asian journal of tropical medicine and public health. 2001;32(2):369-82.
24. Tesfahuneygn G, Medhin G, Legesse M. *Adherence to Anti-tuberculosis treatment and treatment outcomes among tuberculosis patients in Alamata District, northeast Ethiopia*. BMC research notes. 2015;8(1):503.
25. Amoran O, Osiyale O, Lawal K. *Pattern of default among tuberculosis patients on directly observed therapy in rural primary health care centres in Ogun State, Nigeria*. Journal of Infectious Diseases and Immunity. 2011;3(5):90-5.
26. Gorityala SB, Mateti UV, Venkateswarlu Konuru SM. *Assessment of treatment interruption among pulmonary tuberculosis patients: A cross-sectional study*. Journal of pharmacy & bioallied sciences. 2015;7(3):226.
27. Muture BN, Keraka MN, Kimuu PK, Kabiru EW, Ombeka VO, Oguya F. *Factors associated with default from treatment among tuberculosis patients in Nairobi province, Kenya: a case control study*. BMC public health. 2011;11(1):696.
28. Vijay S, Kumar P, Chauhan LS, Vollepore BH, Kizhakkethil UP, Rao SG. *Risk factors associated with default among new smear positive TB patients treated under DOTS in India*. PloS one. 2010;5(4):e10043.
29. Kurbatova EV, Taylor A, Gammino VM, Bayona J, Becerra M, Danilovitz M, et al. *Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects*. Tuberculosis. 2012;92(5):397-403.
30. Kendall EA, Theron D, Franke MF, Van Helden P, Victor TC, Murray MB, et al. *Alcohol, hospital discharge, and socioeconomic risk factors for default from multidrug resistant tuberculosis treatment in rural South Africa: a retrospective cohort study*. PLoS One. 2013;8(12):e83480.

31. Kuchukhidze G, Kumar A, De Colombani P, Khogali M, Nanava U, Blumberg H, et al. *Risk factors associated with loss to follow-up among multidrug-resistant tuberculosis patients in Georgia*. Public health action. 2014;4(2):S41-S6.
32. INTANG B, Suryawati S. Evaluasi faktor penentu kepatuhan penderita TB Paru minum obat anti tuberkulosis di Puskesmas Kabupaten Maluku Tenggara: Universitas Gadjah Mada; 2004.
33. Philipus F. Faktor-faktor yang mempengaruhi keteraturan berobat penderita TB Paru di Puskesmas Depok: Tesis; 2002.
34. Toman K. *Tuberculosis case-finding and chemotherapy*: Citeseer; 1979.
35. van Hoorn R, Jaramillo E, Collins D, Gebhard A, van den Hof S. *The effects of psycho-emotional and socio-economic support for tuberculosis patients on treatment adherence and treatment outcomes—a systematic review and meta-analysis*. PLoS One. 2016;11(4):e0154095.
36. Shargie EB, Lindtjørn B. *Determinants of treatment adherence among smear-positive pulmonary tuberculosis patients in Southern Ethiopia*. PLoS medicine. 2007;4(2):e37.
37. Hill P, Stevens W, Hill S, Bah J, Donkor S, Jallow A, et al. *Risk factors for defaulting from tuberculosis treatment: a prospective cohort study of 301 cases in the Gambia*. The International Journal of Tuberculosis and Lung Disease. 2005;9(12):1349-54.
38. Javaid A, Shaheen Z, Shafqat M, Khan AH, Ahmad N. *Risk factors for high death and loss-to-follow-up rates among patients with multidrug-resistant tuberculosis at a programmatic management unit*. American journal of infection control. 2017;45(2):190-3.
39. Kruyt M, Kruyt N, Boeree M, Harries AD, Salaniponi F, Van Noord P. *True status of smear-positive pulmonary tuberculosis defaulters in Malawi*. Bulletin of the World Health Organization. 1999;77(5):386.
40. Thiam S, LeFevre AM, Hane F, Ndiaye A, Ba F, Fielding KL, et al. *Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial*. Jama. 2007;297(4):380-6.
41. Kangangi J, Kibuga D, Muli J, Maher D, Billo N, NŌgangŌa L, et al. *Decentralisation of tuberculosis treatment from the main hospitals to the peripheral health units and in the community within Machakos district, Kenya*. The International Journal of Tuberculosis and Lung Disease. 2003;7(9):S5-S13.
42. Holtz TH, Lancaster J, Laserson K, Wells C, Thorpe L, Weyer K. *Risk factors associated with default from multidrug-resistant tuberculosis treatment, South Africa, 1999–2001*. The International Journal of Tuberculosis and Lung Disease. 2006;10(6):649-55.
43. Sanchez-Padilla E, Marquer C, Kalon S, Qayyum S, Hayrapetyan A, Varaine F, et al. *Reasons for defaulting from drug-resistant tuberculosis treatment in Armenia: a quantitative and qualitative study*. The International Journal of Tuberculosis and Lung Disease. 2014;18(2):160-7.

44. Shringarpure KS, Isaakidis P, Sagili KD, Baxi R. *Loss-to-follow-up on multidrug resistant tuberculosis treatment in Gujarat, India: the when and who of it.* PloS one. 2015;10(7):e0132543.
45. Breen RA, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmes W, et al. *Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection.* Thorax. 2006;61(9):791-4.
46. Chang K, Leung C, Tam C. *Risk factors for defaulting from anti-tuberculosis treatment under directly observed treatment in Hong Kong.* The International Journal of Tuberculosis and Lung Disease. 2004;8(12):1492-8.
47. Brust JC, Gandhi NR, Carrara H, Osburn G, Padayatchi N. *High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000–2003.* The international journal of tuberculosis and lung disease. 2010;14(4):413-9.
48. Gler M, Podewils L, Munez N, Galipot M, Quelapio M, Tupasi T. *Impact of patient and program factors on default during treatment of multidrug-resistant tuberculosis.* The International Journal of Tuberculosis and Lung Disease. 2012;16(7):955-60.
49. Ho J, Byrne AL, Linh NN, Jaramillo E, Fox GJ. *Decentralized care for multidrug-resistant tuberculosis: a systematic review and meta-analysis.* Bulletin of the World Health Organization. 2017;95(8):584.
50. Toczek A, Cox H, Du Cros P, Cooke G, Ford N. *Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis.* The International Journal of Tuberculosis and Lung Disease. 2013;17(3):299-307.
51. Pinidiyapathirage J, Senaratne W, Wickremasinghe R. *Prevalence and predictors of default with tuberculosis treatment in Sri Lanka.* Southeast Asian J Trop Med Public Health. 2008;39(6):1076-82.
52. Jakubowiak W, Bogorodskaya E, Borisov S, Danilova I, Kourbatova E. *Treatment interruptions and duration associated with default among new patients with tuberculosis in six regions of Russia.* International Journal of Infectious Diseases. 2009;13(3):362-8.
53. Organization WH. *Definitions and reporting framework for tuberculosis–2013 revision.* 2013.
54. Noerfitri N, Sutiawan R, Wahyono TYM, Hartono PA. *Influence of Decentralization and Type of Patient on Loss to Follow-up among Multidrug-Resistant Tuberculosis Patients in Indonesia from 2014 to 2015.* Kesmas: National Public Health Journal. 2019;13(3):105-11.
55. Kim DH, Kim HJ, Park S-K, Kong S-J, Kim YS, Kim T-H, et al. *Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis.* American journal of respiratory and critical care medicine. 2008;178(10):1075-82.
56. Surya A, Setyaningsih B, Suryani Nasution H, Gita Parwati C, Yuzwar YE, Osberg M, et al. *Quality tuberculosis Care in Indonesia: using patient pathway analysis to optimize public–private collaboration.* The Journal of infectious diseases. 2017;216(suppl_7):S724-S32.

57. Milanov V, Falzon D, Zamfirova M, Varleva T, Bachiyiska E, Koleva A, et al. *Factors associated with treatment success and death in cases with multidrug-resistant tuberculosis in Bulgaria, 2009–2010*. International journal of mycobacteriology. 2015;4(2):131-7.
58. Redner P, Ramos JP. *Factors associated with loss to follow-up and death in cases of drug-resistant tuberculosis (DR-TB) treated at a reference center in Cad Saúde Pública*. 2018;34(5):e00048217.
59. Chung-Delgado K, Guillen-Bravo S, Revilla-Montag A, Bernabe-Ortiz A. *Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors*. PloS one. 2015;10(3):e0119332.
60. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. *The growing burden of tuberculosis: global trends and interactions with the HIV epidemic*. Archives of internal medicine. 2003;163(9):1009-21.
61. Samuels JP, Sood A, Campbell JR, Khan FA, Johnston JC. *Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis*. Scientific reports. 2018;8(1):4980.
62. Laserson KF, Thorpe L, Leimane V, Weyer K, Mitnick C, Riekstina V, et al. *Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis*. The International Journal of Tuberculosis and Lung Disease. 2005;9(6):640-5.
63. Franke MF, Appleton SC, Bayona J, Arteaga F, Palacios E, Llaro K, et al. *Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment*. Clinical infectious diseases. 2008;46(12):1844-51.
64. Dale K, Tay E, Trevan P, Denholm J. *Mortality among tuberculosis cases in Victoria, 2002–2013: case fatality and factors associated with death*. The International Journal of Tuberculosis and Lung Disease. 2016;20(4):515-23.
65. Mathew T, Ovsyanikova T, Shin S, Gelmanova I, Balbuena D, Atwood S, et al. *Causes of death during tuberculosis treatment in Tomsk Oblast, Russia*. The International Journal of Tuberculosis and Lung Disease. 2006;10(8):857-63.
66. Yen Y-F, Feng J-Y, Pan S-W, Chuang P-H, Su V-F, Su W-J. *Determinants of mortality in elderly patients with tuberculosis: a population-based follow-up study*. Epidemiology & Infection. 2017;145(7):1374-81.
67. Aljadani R, Ahmed AE, Hamdan A-J. *Tuberculosis mortality and associated factors at King Abdulaziz Medical City Hospital*. BMC infectious diseases. 2019;19(1):427.
68. Huq KE, Moriyama M, Zaman K, Chisti MJ, Long J, Islam A, et al. *Health seeking behaviour and delayed management of tuberculosis patients in rural Bangladesh*. BMC infectious diseases. 2018;18(1):515.
69. Alipanah N, Jarlsberg L, Miller C, Linh NN, Falzon D, Jaramillo E, et al. *Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies*. PLoS medicine. 2018;15(7):e1002595.